BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 34419679)

  • 21. Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis.
    Pelaia C; Crimi C; Benfante A; Caiaffa MF; Campisi R; Candia C; Carpagnano GE; Carrieri I; D'Amato M; Detoraki A; Barbaro MPF; Lombardo N; Macchia L; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Ricciardi L; Scichilone N; Scioscia G; Spadaro G; Tondo P; Uletta Lionetti S; Valenti G; Vatrella A; Crimi N; Pelaia G
    Respirology; 2024 Jun; ():. PubMed ID: 38847185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis.
    Takabayashi T; Asaka D; Okamoto Y; Himi T; Haruna S; Yoshida N; Kondo K; Yoshikawa M; Sakuma Y; Shibata K; Suzuki M; Kobayashi M; Kawata R; Tsuzuki K; Okano M; Higaki T; Takeno S; Kodama S; Yonekura S; Saito H; Nozaki A; Otori N; Fujieda S
    Am J Rhinol Allergy; 2021 Nov; 35(6):861-870. PubMed ID: 33840229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.
    Kavanagh JE; Hearn AP; Dhariwal J; d'Ancona G; Douiri A; Roxas C; Fernandes M; Green L; Thomson L; Nanzer AM; Kent BD; Jackson DJ
    Chest; 2021 Feb; 159(2):496-506. PubMed ID: 32882249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effects of Benralizumab on Lung Volumes and Airway Resistance in Severe Eosinophilic Asthma: A Real-World Study.
    Madeira Gerardo A; da Silva Alves C; Gomes M; Pardal C; Sokolova A; Liberato H; Mendes A; Tonin FS; Duarte-Ramos F; Lopes C
    Cureus; 2024 Jan; 16(1):e52452. PubMed ID: 38371150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
    Pelaia C; Benfante A; Busceti MT; Caiaffa MF; Campisi R; Carpagnano GE; Crimi N; D'Amato M; Foschino Barbaro MP; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Pelaia G; Portacci A; Ricciardi L; Scichilone N; Scioscia G; Triggiani M; Valenti G; Vatrella A; Crimi C
    Front Immunol; 2023; 14():1121237. PubMed ID: 37063895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational Study.
    Le TT; Emmanuel B; Katial R; Tran TN; Kwiatek JJ; Cohen DS; Daniel SR; Cao Y; Shih VH; Melcón MG; Devouassoux G; Pelaia G;
    J Asthma Allergy; 2024; 17():313-324. PubMed ID: 38595692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study.
    Bravo-Gutiérrez FJ; Miralles-López JC; Valverde-Molina J; Alemany Francés ML; Andújar-Espinosa R; Castilla-Martínez M; Avilés-Inglés MJ; Mora-González A; Pajarón-Fernández MJ; Cabrejos-Perotti S; Meseguer-Arce J; Flores Martín I; Pérez-Fernández V;
    Int Arch Allergy Immunol; 2024; 185(3):253-259. PubMed ID: 38035559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
    Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use.
    Jackson DJ; Burhan H; Menzies-Gow A; Pfeffer P; Nanzer A; Garcia Gil E; Morris T; Tran TN; Hirsch I; Dube S
    J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1534-1544.e4. PubMed ID: 35202871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Comorbid Patient in the Spotlight: Efficacy of Benralizumab on Chronic Rhinosinusitis with Nasal Polyp Outcomes in Presence of Severe Asthma.
    De Corso E; D'Amato M; Carpagnano GE; Pelaia G; Bonini M
    Curr Allergy Asthma Rep; 2023 May; 23(5):237-248. PubMed ID: 36995525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.
    Bachert C; Han JK; Desrosiers MY; Gevaert P; Heffler E; Hopkins C; Tversky JR; Barker P; Cohen D; Emson C; Martin UJ; Shih VH; Necander S; Kreindler JL; Jison M; Werkström V
    J Allergy Clin Immunol; 2022 Apr; 149(4):1309-1317.e12. PubMed ID: 34599979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A real world study of anti-IgE monoclonal antibody in the treatment of allergic united airway disease].
    Sui HJ; Zhen Z; Wang QG; Cong TC; Huang JJ; Hu Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Feb; 57(2):273-280. PubMed ID: 36797588
    [No Abstract]   [Full Text] [Related]  

  • 33. Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities.
    Crimi C; Campisi R; Cacopardo G; Intravaia R; Nolasco S; Porto M; Pelaia C; Crimi N
    World Allergy Organ J; 2020 Sep; 13(9):100462. PubMed ID: 32994855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report.
    Pham DN
    J Med Case Rep; 2021 Mar; 15(1):103. PubMed ID: 33673870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression.
    Pelaia C; Crimi C; Benfante A; Caiaffa MF; Calabrese C; Carpagnano GE; Ciotta D; D'Amato M; Macchia L; Nolasco S; Pelaia G; Pellegrino S; Scichilone N; Scioscia G; Spadaro G; Valenti G; Vatrella A; Crimi N
    J Asthma Allergy; 2021; 14():163-173. PubMed ID: 33654413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps.
    Tiotiu A; Mendez-Brea P; Ioan I; Romero-Fernandez R; Oster JP; Hoang TC; Roux P; Ochoa-Gutierrez DC; Bonniaud P; de Blay F; Gonzalez-Barcala FJ
    Clin Rev Allergy Immunol; 2023 Apr; 64(2):179-192. PubMed ID: 35420388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Short-term efficacy of anti-IgE monoclonal antibody in patients with recurrent chronic rhinosinusitis with nasal polyps combined with asthma].
    Shen S; Lou HF; Yan B; Wang Y; Cao FF; Xiong W; Wang CS; Zhang L
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2021 Oct; 56(10):1035-1041. PubMed ID: 34666463
    [No Abstract]   [Full Text] [Related]  

  • 38. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma.
    Bleecker ER; Wechsler ME; FitzGerald JM; Menzies-Gow A; Wu Y; Hirsch I; Goldman M; Newbold P; Zangrilli JG
    Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30139780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of response of severe eosinophilic asthmatic patients to benralizumab.
    Miralles-López JC; Andújar-Espinosa R; Bravo-Gutiérrez FJ; Castilla-Martínez M; Flores-Martín I; Alemany-Francés ML; Pajarón-Fernández MJ; Mora-González A; Cabrejos-Perotti S; El-Molaka Z; Meseguer-Arce J; Avilés-Inglés MJ; Valverde-Molina J; Pérez-Fernández V;
    Allergol Immunopathol (Madr); 2022; 50(6):163-168. PubMed ID: 36335460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.